CCNY抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P03504(HLA-DOA Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P03504(HLA-DOA Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

**Background of CCNY Antibody**

CCNY (Cyclin Y) is a regulatory protein belonging to the cyclin family, which plays a critical role in cell cycle progression by activating cyclin-dependent kinases (CDKs). Specifically, CCNY interacts with CDK14 and CDK16 to modulate the Wnt/β-catenin signaling pathway, a key pathway involved in cell proliferation, differentiation, and development. Unlike classical cyclins, CCNY is membrane-associated due to its N-terminal palmitoylation, enabling it to phosphorylate LRP6 (a Wnt co-receptor) and enhance Wnt signaling.

Antibodies targeting CCNY are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate CCNY's role in diseases such as cancer, where its overexpression correlates with tumor growth and poor prognosis. Additionally, CCNY antibodies aid in exploring neurodevelopmental disorders, as CCNY is implicated in synaptic plasticity and neurodegenerative conditions like Alzheimer’s disease.

These antibodies are typically generated using immunogenic peptides or recombinant CCNY protein, ensuring specificity for human, mouse, or rat homologs. Their applications extend to basic research and drug discovery, particularly in targeting Wnt-driven malignancies. Validation of CCNY antibodies includes testing for cross-reactivity and verifying knockdown/overexpression models, ensuring reliability in diverse experimental settings.